Please login to the form below

Not currently logged in
Email:
Password:

Transgene

This page shows the latest Transgene news and features for those working in and with pharma, biotech and healthcare.

Transgene slumps as viral cancer therapy fails phase 3 trial

Transgene slumps as viral cancer therapy fails phase 3 trial

French biotech Transgene has abandoned a phase 3 trial of its SillaJen-partnered liver cancer therapy after an interim analysis suggested almost no chance of a positive outcome. ... Transgene said in a statement that South Korean biotech SillaJen had

Latest news

  • AZ invests more in IO with Transgene oncolytic virus deal AZ invests more in IO with Transgene oncolytic virus deal

    However this candidate is based on Transgene’s proprietary next-generation viral platform. ... AstraZeneca has similar plans to combined Transgene’s oncolytic viruses withits in-house pipeline ofImmuno-oncology (IO) treatments.

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Both vectors contain the transgenes for PSA and multiple T-cell co-stimulatory molecules. .

  • Sanofi to act as contract manufacturer for Transgene Sanofi to act as contract manufacturer for Transgene

    Sanofi has formed an innovative collaboration with fellow French company Transgene that will see it act at the biotech's contract manufacturing organisation (CMO). ... But in return for its investment Transgene will be its preferred customer for 15 years

  • Regional plans

    As part of the Institut Merieux group, Transgene would be well placed to be able to address the European market with JX 594 for the treatment of solid tumours. ... 181. Transgene/Jennerex ##. JX 594 for the treatment of solid tumours.

  • Jennerex and Transgene cancer partnership

    worldwide. Transgene will be responsible for development costs and clinical development in its licensed territories, pursuant to the JX-594 global development plan. ... Transgene will commercialise and hold the right to manufacture JX-594 in its agreed

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid tumours with trial results due between now and the end of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics